论文部分内容阅读
目的探讨非小细胞肺癌组织中Sirt1的表达及其对患者预后的影响。方法收集264例非小细胞肺癌手术治疗患者的临床病理资料和术后生存随访资料,通过免疫组化的方法检测Sirt1的表达,分析其与患者临床病理指标及预后之间的关系。结果 Sirt1在非小细胞肺癌组织中明显高于周围正常肺组织,差异具有统计学意义(P<0.05),并且在肿瘤组织(尤其是鳞状细胞癌)中Sirt1表达越高,患者预后越差。而与年龄、性别、肿瘤组织学类型、分化程度、淋巴结转移、远处转移、临床TNM分期等无明显关系(均P>0.05)。结论 Sirt1在非小细胞肺癌(尤其鳞癌)组织中的表达水平有望成为预测非小细胞肺癌患者预后的生物标志物。
Objective To investigate the expression of Sirt1 in non-small cell lung cancer and its effect on the prognosis of patients. Methods The clinicopathological data and survival follow-up data of 264 NSCLC patients were collected. The expression of Sirt1 was detected by immunohistochemistry and the relationship between Sirt1 and the clinicopathological parameters and prognosis was analyzed. Results Sirt1 in non-small cell lung cancer was significantly higher than that in the surrounding normal lung tissue (P <0.05), and the higher Sirt1 expression in tumor tissues (especially squamous cell carcinoma), the worse the prognosis . There was no significant correlation between age, sex, histological type, differentiation, lymph node metastasis, distant metastasis and clinical TNM stage (all P> 0.05). Conclusion The expression level of Sirt1 in non-small cell lung cancer (especially squamous cell carcinoma) is expected to become a biomarker to predict the prognosis of patients with non-small cell lung cancer.